Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients

INTRODUCTION: Although transarterial radioembolization (TARE) using yttrium-90 ((90)Y) is a treatment option for large hepatocellular carcinoma (HCC), a fraction of patients are ineligible for TARE due to high lung shunt fraction (LSF). METHODS: We evaluated if treatment with transarterial chemoembo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Sung Won, Cho, Heejin, Shin, Hyunjae, Park, Jeayeon, Kim, Ju Yeon, Hong, Ji Hoon, Hur, Moon Haeng, Park, Min Kyung, Lee, Yun Bin, Yu, Su Jong, Lee, Myungsu, Kim, Yoon Jun, Paeng, Jin Chul, Yoon, Jung-Hwan, Chung, Jin Wook, Lee, Jeong-Hoon, Kim, Hyo-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013818/
https://www.ncbi.nlm.nih.gov/pubmed/36925930
http://dx.doi.org/10.3389/fonc.2023.1081479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013818/
https://www.ncbi.nlm.nih.gov/pubmed/36925930
http://dx.doi.org/10.3389/fonc.2023.1081479

Ejemplares similares